SHANGHAI, March 18, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a letter of intent (the “Letter of Intent”) with Hasten Biopharmaceuticals (Asia) Limited (the ”Seller”) in relation to the possible acquisition (the ”Possible Acquisition”) of the entire equity interest in Hasten Biopharmaceuticals (SG) Pte. Ltd., a wholly-owned subsidiary of the Seller (the ”Target Company”). The Possible Acquisition is expected to supplement the Company’s existing pipeline and is intended to further expand its scale and strategic presence across the Asia-Pacific region.
Hasten Biopharmaceuticals (SG) Pte. Ltd. is a company incorporated in Singapore principally engaged in the commercialization of prescription pharmaceutical products, with a strategic focus on chronic diseases and acute/critical care areas, in particular in the cardiovascular and metabolic segments. It has built a commercial platform, and holds asset rights, including Marketing Authorization Holder (MAH) rights, trademarks and broad commercial rights for 14 branded chronic disease products across the Asia-Pacific region, benefiting tens of millions of patients with chronic diseases.
Everest Medicines shall pay to the Seller a refundable deposit (the ”Refundable Deposit”) of RMB200 million no later than five business days following the execution of the Letter of Intent. The Refundable Deposit shall be converted into a part of the consideration under a Possible Acquisition (if it materializes), or refunded to the Company, as mutually agreed between the parties. The Company plans to fund the Refundable Deposit with its existing resources.
Following the signing of the Letter of Intent, the Seller will authorize Hasten Biopharmaceuticals (SG) Pte. Ltd management to allow the Company to conduct due diligence, and agree to a six-month exclusivity period (the ”Exclusivity Period”).
With a population of approximately 600 million, the Southeast Asia region has significant unmet medical needs and substantial market potential in chronic disease management. Everest’s product pipeline also focuses on chronic disease therapeutic areas such as CKM (cardiovascular, kidney, and metabolic diseases), demonstrating potential synergies with Hasten Biopharmaceuticals’ product portfolio and commercial platform.
Over the past three years, Everest Medicines has established a leading commercialization platform for innovative therapies in chronic diseases in China, as evidenced by the robust sales and growth of NEFECON®. The Company aims to expand its presence in the Asia-Pacific region and, over time, evolve into a leading global biopharmaceutical company. Beyond Mainland China, the Company’s commercialized products, including NEFECON®, VELSIPITY® and XERAVA®, have received or are progressing toward new drug application approvals in authorized Asian markets, with inclusion in local reimbursement regimes.
Through the Possible Acquisition, Everest Medicines could accelerate the commercialization of its existing products in Asian markets, thereby driving growth in overseas sales revenue, and would represent a significant step toward its broader global expansion strategy by extending its commercial footprint across Asia.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.
About Hasten Biopharmaceuticals (Asia) Limited and Hasten Biopharmaceuticals (SG) Pte. Ltd.
Hasten Biopharmaceuticals (Asia) Limited is a company incorporated in the Cayman Islands with limited liability and is principally engaged in investment holding.
Hasten Biopharmaceuticals (SG) Pte. Ltd. is a company incorporated in Singapore with limited liability and principally engaged in commercialization of prescription pharmaceutical products with strategic focus on chronic diseases and acute/critical care areas, in particular in the cardiovascular and metabolism segments. Hasten Biopharmaceuticals (SG) Pte. Ltd. holds the asset rights, including Marketing Authorization Holder (MAH) rights, trademark and broad commercial rights for 14 branded chronic disease products across multiple countries and regions in the Asia-Pacific region.
Forward-Looking Statements:
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
ข่าวที่เกี่ยวข้อง
- MTR Lab and ZGC Science City Ltd Establish Ecosystem Partnership
- Vinova Named to Financial Times Top 500 High-Growth Companies Asia-Pacific for Third Consecutive Year
- WePlay Launches Charity Initiative in Malaysia, Bringing Warmth and Care to Children at a Kuala Lumpur Orphanage
- Alimentaria+Hostelco 2026 ตอกย้ำความเป็นผู้นำในการจัดงานครั้งประวัติศาสตร์
